Regulatory FDA approves new high dose Spinraza regimen for SMA PharmaTimesUpdated dosing offers meaningful clinical benefitRegulatoryRare DiseaseRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) PharmaTimes Updated dosing offers meaningful clinical benefit RegulatoryRare DiseaseRead full story Post navigation Previous: Viridian reports positive results from elegrobart phase 3 trialNext: Ambrosia adds a megaround for obesity drugs Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
